Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EIK1005 + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- Eikon Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
EIK1005 + pembrolizumab is an investigational combination therapy consisting of EIK1005, a novel small-molecule inhibitor of Werner (WRN) helicase, and pembrolizumab, a marketed anti-PD-1 monoclonal antibody (Keytruda). Developed by Eikon Therapeutics in collaboration with Merck & Co., this combination is designed to exploit synthetic lethality in microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumor cells, which depend on the WRN helicase pathway to maintain genome integrity, while simultaneously enhancing the immune system's ability to target and destroy cancer cells. The combination is being evaluated in a Phase 1/2 clinical trial (NCT07262619) for patients with advanced solid tumors, including MSI-H/dMMR tumors.
- Other names
- EIK-1005 + KeytrudaEIK-1005 + pembrolizumabEIK1005 + KeytrudaKeytruda + EIK-1005Keytruda + EIK1005pembrolizumab + EIK-1005pembrolizumab + EIK1005
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)PDCD1 (Programmed cell death protein 1 receptor)PDCD1LG2 (Programmed cell death 1 ligand 2)RNF4WRN (Werner syndrome ATP-dependent helicase)
Beyond the preview
Go deeper on EIK1005 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EIK1005 + pembrolizumab.